{"id":"xy0206","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, XY0206 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"XY0206 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:13.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07162116","phase":"PHASE1","title":"A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants","status":"RECRUITING","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2025-07-06","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation","enrollment":45},{"nctId":"NCT06823232","phase":"PHASE1","title":"A Study on the Substance Balance of [14C]XY0206 in Healthy Adult Chinese Men","status":"COMPLETED","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2024-11-06","conditions":"Metabolism of Radioactive Substances","enrollment":6},{"nctId":"NCT05876832","phase":"PHASE3","title":"A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)","status":"NOT_YET_RECRUITING","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2023-06-15","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation","enrollment":312},{"nctId":"NCT04471064","phase":"PHASE1","title":"A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2020-09-15","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT03658070","phase":"PHASE1","title":"A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours","status":"UNKNOWN","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2018-12-19","conditions":"Advanced or Metastatic Solid Tumours","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"XY0206","genericName":"XY0206","companyName":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","companyId":"shijiazhuang-yiling-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XY0206 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}